Onco-Innovations Limited (NEO:ONCO)

Canada flag Canada · Delayed Price · Currency is CAD
1.650
-0.070 (-4.07%)
Nov 7, 2025, 4:00 PM EST
-4.07%
Market Cap92.10M
Revenue (ttm)84.79K
Net Income (ttm)-10.83M
Shares Out55.82M
EPS (ttm)-0.27
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,900
Average Volume29,875
Open1.700
Previous Close1.720
Day's Range1.650 - 1.700
52-Week Range0.560 - 2.800
Betan/a
RSI56.58
Earnings DateDec 12, 2025

About Onco-Innovations

Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments. The company’s lead product candidate is ONC010, a novel inhibitor of the DNA repair enzyme a Polynucleotide Kinase 3′-Phosphatase (PNKP) in a nanoparticle formulation based on the drug delivery technology. Onco-Innovations Limited is headquartered in Calgary, Canada. [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Thomas O’Shaughnessy
Employees 1
Stock Exchange Cboe Canada
Ticker Symbol ONCO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.